VHCP Management II as of June 30, 2016
Portfolio Holdings for VHCP Management II
VHCP Management II holds 23 positions in its portfolio as reported in the June 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Avexis | 22.8 | $38M | 1.0M | 36.49 | |
| Edge Therapeutics | 11.8 | $20M | 1.9M | 10.11 | |
| Dbv Technologies | 10.5 | $17M | 374k | 46.67 | |
| BioCryst Pharmaceuticals (BCRX) | 9.8 | $16M | 5.7M | 2.84 | |
| Ascendis Pharma A S (ASND) | 5.8 | $9.6M | 721k | 13.27 | |
| Regenxbio Inc equity us cm (RGNX) | 4.8 | $8.0M | 1000k | 8.00 | |
| Heron Therapeutics (HRTX) | 4.4 | $7.3M | 406k | 18.05 | |
| Alcobra | 3.9 | $6.5M | 1.5M | 4.49 | |
| Cytomx Therapeutics (CTMX) | 3.6 | $5.9M | 578k | 10.22 | |
| Axovant Sciences | 3.3 | $5.5M | 430k | 12.84 | |
| Akari Therapeutics | 3.0 | $5.0M | 370k | 13.49 | |
| Coherus Biosciences (CHRS) | 2.6 | $4.4M | 259k | 16.89 | |
| Cynapsus Therapeutics | 2.5 | $4.2M | 253k | 16.63 | |
| Beigene (BGNE) | 2.1 | $3.5M | 119k | 29.80 | |
| ARCA biopharma | 1.9 | $3.1M | 1.1M | 2.90 | |
| Global Blood Therapeutics In | 1.7 | $2.8M | 170k | 16.59 | |
| D Stemline Therapeutics | 1.3 | $2.1M | 316k | 6.77 | |
| Ocera Therapeutics | 1.1 | $1.8M | 948k | 1.90 | |
| Aeglea Biotherapeutics | 0.9 | $1.5M | 350k | 4.36 | |
| Lipocine | 0.8 | $1.3M | 420k | 3.04 | |
| Adverum Biotechnologies | 0.5 | $885k | 280k | 3.16 | |
| Zafgen | 0.5 | $848k | 142k | 5.99 | |
| Pronai Therapeutics | 0.2 | $260k | 131k | 1.99 |
